Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 6 publications
Discovery of Potential First-in-Class Dual Ligand-Directed Degrader and Antagonist of the Androgen Receptor: BMS-986365.
Journal: Journal of medicinal chemistry
Published: July 10, 2026
Applied Astrobiology: An Integrated Approach to the Future of Life in Space.
Journal: Astrobiology
Published: April 22, 2025
Discovery of BMS-986365, a First-in-Class Dual Androgen Receptor Ligand-Directed Degrader and Antagonist, for the Treatment of Advanced Prostate Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 12, 2025
Immunogenicity and Vaccine Shedding After 1 or 2 Doses of rVSVΔG-ZEBOV-GP Ebola Vaccine (ERVEBO®): Results From a Phase 2, Randomized, Placebo-controlled Trial in Children and Adults.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: August 23, 2023
Estimation of the correlates of protection of the rVSVΔG-ZEBOV-GP Zaire ebolavirus vaccine: a post-hoc analysis of data from phase 2/3 clinical trials.
Journal: The Lancet. Microbe
Published: September 02, 2020
Showing 1-6 of 6
Last Updated: 09/26/2026